The efficacy of fluoxetine in improving physical symptoms associated with premenstrual dysphoric disorder

British Journal of Obstetrics and Gynaecology

Volumn 108, Issue 5, 2001, Pages 462-468

  Steiner, Meir ^a   Romano, Steven J ^b   Babcock, Susan ^b   Dillon, Julia ^b   Shuler, Cathy ^b   Berger, Charlene ^c   Carter, Diana ^d   Reid, Robert ^e   Stewart, Donna ^f   Steinberg, Susanne ^c   Judge, Rajinder ^b  

^a ST JOSEPH S HOSPITAL   (Canada)

^b ELI LILLY AND COMPANY   (United States)

^c ST MARY S HOSPITAL   (Canada)

^d British Columbia Women's Reproductive Psychiatric Program   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DYSPHORIA; FEMALE; HEADACHE; HUMAN; LUTEAL PHASE; MAJOR CLINICAL STUDY; MASTALGIA; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; SYMPTOMATOLOGY;

ADULT; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; FEMALE; FLUOXETINE; HUMANS; PREMENSTRUAL SYNDROME; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0034964436     PISSN: 03065456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-5456(00)00120-0     Document Type: Article

References (33)

1. DSM-IV
2. The epidemiology and social impact of premenstrual symptoms
3. Late luteal phase dysphoric disorder in young women
4. The epidemiology of premenstrual symptoms in a population-based sample of 2650 urban women: Attributable risk and risk factors
5. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome
6. Effect of clomipramine on premenstrual syndrome
7. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder
8. Clomipramine effectively reduces premenstrual irritability and dysphoria: A placebo-controlled trial
9. Paroxetine as a treatment for premenstrual dysphoric disorder
10. Fluoxetine in the treatment of premenstrual dysphoria
11. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: A randomized controlled trial (Sertraline Premenstrual Dysphoric Collaborative Study Group)
12. Fluoxetine in the treatment of premenstrual dysphoria
13. The measurement of premenstrual mood symptoms
14. Prospective assessment of menstrually related mood disorders
15. Clinical applications of visual analogue scales: A critical review
16. Premenstrual syndrome: Documentation by a linear analog scale compared with two descriptive scales
17. Premenstrual tension syndrome: The development of research diagnostic criteria and new rating scales
18. Fluoxetine's spectrum of action in premenstrual syndrome
19. Treatment of premenstrual syndrome with fluoxetine: A double- blind, placebo-controlled, crossover study
20. Fluoxetine in the treatment of premenstrual syndrome
21. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: The calendar of premenstrual experiences
22. Citalopram in premenstrual dysphoria: Is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?
23. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: A placebo-controlled trial
24. The role of serotonin in premenstrual syndrome
25. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome
26. Therapeutic effect of sleep deprivation in patients with premenstrual syndrome
27. Morning versus evening bright light treatment of late luteal phase dysphoric disorder
28. Allopregnanolone concentrations and premenstrual syndrome
29. Progesterone metabolite allopregnanolone in women with premenstrual syndrome
30. Neuroactive steroids
31. The anxiolytic-like effects of the neurosteroid allopregnanolone: Interactions with GABA(A) receptors
32. Fluoxetine-elicited changes in brain neurosteroid content measured by negative ion mass fragmentography
33. Estrogen increases the density of 5-hydroxytryptamine(2A) receptors in cerebral cortex and nucleus accumbens in the female rat